Short Interest in Palisade Bio, Inc. (NASDAQ:PALI) Increases By 97.0%

Palisade Bio, Inc. (NASDAQ:PALI) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 291,500 shares, an increase of 97.0% from the February 28th total of 148,000 shares. Based on an average daily trading volume, of 566,700 shares, the short-interest ratio is presently 0.5 days. Approximately 10.6% of the shares of the company are short sold.

Palisade Bio Price Performance

NASDAQ:PALI traded up $0.01 during midday trading on Friday, reaching $0.70. The stock had a trading volume of 25,056 shares, compared to its average volume of 761,427. The stock has a market capitalization of $1.94 million, a P/E ratio of -0.05 and a beta of 1.49. Palisade Bio has a 1-year low of $0.65 and a 1-year high of $9.65. The firm’s fifty day simple moving average is $1.04 and its 200-day simple moving average is $2.10.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.39) by $1.70. On average, equities research analysts anticipate that Palisade Bio will post -12.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Palisade Bio

A hedge fund recently bought a new stake in Palisade Bio stock. JPMorgan Chase & Co. purchased a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned 0.54% of Palisade Bio as of its most recent SEC filing. Institutional investors own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.